Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 4/20 | 0.44 |
| ▸ | CDK8 | P49336 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15341092 | 0.85 | TRPA1 (0.46) | TRPA1CCNCCDK8APPSRC | |
| SCHEMBL13680555 | 0.83 | TGFBR1 (0.55) | TRPA1TGFBR1MAPK14 | |
| SCHEMBL15340894 | 0.82 | TRPA1 (0.44) | TRPA1CCNCCDK8APPSRC | |
| SCHEMBL15341093 | 0.82 | CYP11B2 (0.50) | TRPA1CYP11B1CYP11B2CCNCCDK8 | |
| SCHEMBL15344154 | 0.79 | TRPA1 (0.46) | TRPA1CCNCCDK8APPTGFBR1 | |
| SCHEMBL15344153 | 0.78 | TRPA1 (0.48) | TRPA1CYP11B1CYP11B2CCNCCDK8 | |
| SCHEMBL15345120 | 0.77 | TRPA1 (0.47) | TRPA1CYP11B2CCNCCDK8APP | |
| SCHEMBL15345066 | 0.77 | TRPA1 (0.47) | TRPA1CCNCCDK8APPTGFBR1 | |
| SCHEMBL15345171 | 0.77 | TRPA1 (0.47) | TRPA1CCNCCDK8APPTGFBR1 | |
| SCHEMBL15344156 | 0.77 | CCR1 (0.47) | TRPA1CCNCCDK8APPTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | TRPA1 4766/4885CYP11B1 10/4885CYP11B2 21/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885CYP11B1 20/4885CYP11B2 19/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885CYP11B1 20/4885CYP11B2 19/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | TRPA1 4766/4885CYP11B1 10/4885CYP11B2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.